3,007
Views
35
CrossRef citations to date
0
Altmetric
Articles

Development and characterization of folic acid-conjugated chitosan nanoparticles for targeted and controlled delivery of gemcitabinein lung cancer therapeutics

, , , &
Pages 1530-1538 | Received 06 Aug 2016, Accepted 08 Nov 2016, Published online: 29 Nov 2016

References

  • Banerjee T, Mitra S, Kumar Singh A, Kumar Sharma R, Maitra A. 2002. Preparation, characterization and biodistribution of ultrafine chitosan nanoparticles. Int J Pharm. 243:93–105.
  • Bareford LM, Swaan PW. 2007. Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev. 59:748–758.
  • Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. 2014. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 66:2–25.
  • Chen H, Xie LQ, Qin J, Jia Y, Cai X, Nan W, et al. 2015. Surface modification of PLGA nanoparticles with biotinylated chitosan for the sustained in vitro release and the enhanced cytotoxicity of epirubicin. Colloids Surf B Biointerfaces 138:1–9.
  • Chen J, Huang L, Lai H, Lu C, Fang M, Zhang Q, Luo X. 2014. Methotrexate-loaded PEGylated chitosan nanoparticles: synthesis, characterization, and in vitro and in vivo antitumoral activity. Mol Pharm. 11:2213–2223.
  • Cho YW, Park SA, Han TH, Son DH, Park JS, Oh SJ, et al. 2007. In vivo tumor targeting and radionuclide imaging with self-assembled nanoparticles: mechanisms, key factors, and their implications. Biomaterials 28:1236–1247.
  • Fruh M, Gillessen S, Cerny T, Demmer R, D'Addario G. 2008. Two-weekly gemcitabine fixed dose rate and oxaliplatin combination chemotherapy for advanced non-small-cell lung cancer. Lung Cancer 62:344–350.
  • Fukuda MN, Ohyama C, Lowitz K, Matsuo O, Pasqualini R, Ruoslahti E, Fukuda M. 2000. A peptide mimic of E-selectin ligand inhibits sialyl Lewis X-dependent lung colonization of tumor cells. Cancer Res. 60:450–456.
  • Garg NK, Dwivedi P, Campbell C, Tyagi RK. 2012. Site specific/targeted delivery of gemcitabine through anisamide anchored chitosan/poly ethylene glycol nanoparticles: an improved understanding of lung cancer therapeutic intervention. Eur J Pharm Sci. 47:1006–1014.
  • Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. 1994. Biodegradable long-circulating polymeric nanospheres. Science 263:1600–1603.
  • Hsu C, Kuo SH, Hu FC, Cheng AL, Shih JY, Yu CJ, et al. 2008. Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-a randomized phase II trial. Lung Cancer 62:334–343.
  • Jain A, Agarwal A, Majumder S, Lariya N, Khaya A, Agrawal H, Majumdar S, Agrawal GP. 2010. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. J Control Release 148:359–367.
  • Jain A, Jain A, Garg NK, Tyagi RK, Singh B, Katare OP, Webstere TJ, Soni V. 2015. Surface engineered polymeric nanocarriers mediate the delivery of transferrin–methotrexate conjugates for an improved understanding of brain cancer. ActaBiomater 24:140–151.
  • Jain A, Kesharwani P, Garg NK, Jain A, Jain SA, Jain AK, et al. 2015. Galactose engineered solid lipid nanoparticles for targeted delivery of doxorubicin. Colloids and Surf B: Biointerfaces 134:027
  • Jain S, Mathur R, Das M, Swarnakar NK, Mishra AK. 2011. Synthesis, pharmacoscintigraphic evaluation and antitumor efficacy of methotrexate-loaded, folate-conjugated, stealth albumin nanoparticles. Nanomedicine 6:1733–1754.
  • Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ. 2004. Cancer statistics, 2004. CA Cancer J Clin. 54:8–29.
  • Ji J, Zuo P, Wang YL. 2015. Enhanced antiproliferative effect of carboplatin in cervical cancer cells utilizing folate-grafted polymeric nanoparticles. Nanoscale 10:453.
  • Kerr KM. 2001. Pulmonary preinvasive neoplasia. J Clin Pathol. 54:257–271.
  • Kesharwani P, Iyer AK. 2015. Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery. Drug Discov Today 20:536–547.
  • Ko JA, Park HJ, Hwang SJ, Park JB, Lee JS. 2002. Preparation and characterization of chitosan microparticles intended for controlled drug delivery. Int J Pharm. 249:165–174.
  • Koo OM, Rubinstein I, Onyuksel H. 2005. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine 1:193–212.
  • Kumar G, Sharma S, Shafiq N, Khuller GK, Malhotra S. 2012. Optimization, in vitro-in vivo evaluation, and short-term tolerability of novel levofloxacin-loaded PLGA nanoparticle formulation. J Pharm Sci. 101:2165–2176.
  • Lee KD, Choi SH, Kim DH, Lee HY, Choi KC.2015. Self-organized nanoparticles based on chitosan–folic acid and dextran succinate-doxorubicin conjugates for drug targeting. Arch Pharm Res. 37:1546–1553.
  • Mitra S, Gaur U, Ghosh PC, Maitra AN. 2001. Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J Control Release 74:317–323.
  • Moghimi SM, Hunter AC, Murray JC. 2001. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 53:283–318.
  • Na K, Bum Lee T, Park KH, Shin EK, Lee YB, Choi HK. 2003. Self-assembled nanoparticles of hydrophobically-modified polysaccharide bearing vitamin H as a targeted anti-cancer drug delivery system. Eur J Pharm Sci. 18:165–173.
  • Nandini PT, Doijad RC, Shivakumar HN, Dandagi PM. 2015. Formulation and evaluation of gemcitabine-loaded solid lipid nanoparticles. Drug Deliv. 22:647–651.
  • O'Shannessy DJ, Yu G, Smale R, Fu YS, Singhal S, Thiel RP, Somers EB, Vachani A. 2012. Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance. Oncotarget 3:414–425.
  • Rampino A, Borgogna M, Blasi P, Bellich B, Cesaro A. 2013. Chitosan nanoparticles: preparation, size evolution and stability. Int J Pharm. 455:219–228.
  • Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, et al. 2000. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 18:122–130.
  • Singh R, Shakya AK, Naik R, Shalan N. 2015. Stability-indicating HPLC determination of gemcitabine in pharmaceutical formulations. Int J Anal Chem. 2015: Article ID: 862592. doi:10.1155/2015/862592.
  • Tseng CL, Wang TW, Dong GC, Yueh-Hsiu WS, Young TH, Shieh MJ, Lou PJ, Lin FH. 2007. Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting. Biomaterials 28:3996–4005.
  • Wang M, Hu H, Sun Y, Qiu L, Zhang J, Guan G, et al. 2013. A pH-sensitive gene delivery system based on folic acid-PEG-chitosan – PAMAM-plasmid DNA complexes for cancer cell targeting. Biomaterials 34:10120–10132.
  • Wilson B, Samanta MK, Santhi K, Kumar KP, Ramasamy M, Suresh B. 2010. Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine. Nanomedicine 6:144–152.
  • Yu X, Yang G, Shi Y, Su C, Liu M, Feng B, Zhao L. 2015. Intracellular targeted co-delivery of shMDR1 and gefitinib with chitosan nanoparticles for overcoming multidrug resistance. Int J Nanomed. 10:7045–7056.
  • Zhang BF, Xing L, Cui PF, Wang FZ, Xie RL, Zhang JL, et al. 2015. Mitochondria apoptosis pathway synergistically activated by hierarchical targeted nanoparticles co-delivering siRNA and lonidamine. Biomaterials 61:178–189.
  • Zwicke GL, Mansoori GA, Jeffery CJ. 2012. Utilizing the folate receptor for active targeting of cancer nanotherapeutics. Nano Rev. 3:1–11.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.